Ozanimod

Report
34 Pages
August 2018
Region: Global
Citeline
ID: 4775307

Drug Overview
Ozanimod (Celgene) is a sphingosine 1-phosphate (S1P) receptor agonist, with selectivity for the sphingosine 1-phosphate type 1 receptor (S1P1) and sphingosine 1-phosphate receptor 5 (S1P5).

The drug modulates the expression of S1P receptors, which is thought to reduce the overall number of circulating lymphocytes by preventing their migration from secondary lymphoid organs.

The drug is being developed in multiple sclerosis, ulcerative colitis, and Crohn’s disease.

OVERVIEW

Drug Overview
Product Profiles
ozanimod: Crohn's disease
ozanimod: Multiple sclerosis
ozanimod: Ulcerative colitis

LIST OF FIGURES

Figure 29: The authors drug assessment summary of etrolizumab in Crohn’s disease
Figure 6: The authors drug assessment summary of filgotinib in Crohn’s disease
Figure 23: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 23: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 31: Etrolizumab for Crohn’s disease – SWOT analysis
Figure 34: Ozanimod for Crohn’s disease – SWOT analysis
Figure 6: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 27: Tysabri sales for Crohn’s disease in the US, 2016–25

LIST OF TABLES

Table 1: Ozanimod drug profile
Table 2: Ozanimod Phase III trials in Crohn’s disease
Table 3: Ozanimod Phase II data in Crohn’s disease
Table 4: Ozanimod drug profile
Table 28: Tysabri pivotal trial data in Crohn’s disease
Table 6: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Table 7: Ozanimod drug profile

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9730EUR$10,000USD£8,335GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47676EUR$49,000USD£40,842GBP

Table of Contents

Related Topics

Related Reports

Ulcerative Colitis (UC) - Market Insight, Epidemiology And Market Forecast - 2032

Crohn's Disease (CD) Treatment Global Market Report 2024

Global Infliximab Drug Market Report and Forecast 2023-2031

TNF Inhibitors - Global Strategic Business Report

Crohn's Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)